The federal agency announced Wednesday that it will review its "overpayment" process, after it was reported that it clawed back $4.7 billion of overpayments, while another $21.6 billion remains outstanding.
Even though six drug companies have filed lawsuits to halt the Medicare drug negotiation program, the companies have until Oct. 2 to present data on their drugs to CMS, which will make initial price offers in February.